Apolipoproteins in the brain: Implications for neurological and psychiatric disorders

Clinical Lipidology

Volumn 5, Issue 4, 2010, Pages 555-573

  Elliott, David A ^a   Weickert, Cyndi Shannon ^a,b,c   Garner, Brett ^a,d  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

apolipoprotein; brain; CNS; lipid; neurological disease

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN D; APOLIPOPROTEIN E; CLOZAPINE; CLUSTERIN; LIPID; LIPOPROTEIN; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; DISEASE ASSOCIATION; DRUG MECHANISM; GENETIC POLYMORPHISM; HUMAN; LIPID METABOLISM; LIPID TRANSPORT; LIPOPROTEIN METABOLISM; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 77955566963     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.37     Document Type: Review

References (252)

1. Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH: Human plasma lipoprotein [a]. Structural properties. J. Biol. Chem. 258(7), 4582-4589 (1983).
2. Weech PK, Provost P, Tremblay NM et al.: Apolipoprotein D-an atypical apolipoprotein. Prog. Lipid Res. 30(2-3), 259-266 (1991).
3. Eichinger A, Nasreen A, Kim HJ, Skerra A: Structural insight into the dual ligand specificity and mode of high density lipoprotein association of apolipoprotein D. J. Biol. Chem. 282(42), 31068-31075 (2007).
4. Ben Gedalya T, Loeb V, Israeli E, Altschuler Y, Selkoe DJ, Sharon R: a-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic. 10(2), 218-234 (2009).
5. Kwon HJ, Abi-Mosleh L, Wang ML et al.: Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 137(7), 1213-1224 (2009).
6. Weickert CS, Elashoff M, Richards AB et al.: Transcriptome analysis of male-female differences in prefrontal cortical development. Mol. Psychiatry 14(6), 558-561 (2009).
7. Edgar R, Domrachev M, Lash AE: Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30(1), 207-210 (2002).
8. Harris LW, Lockstone HE, Khaitovich P, Weickert CS, Webster MJ, Bahn S: Gene expression in the prefrontal cortex during adolescence: implications for the onset of schizophrenia. BMC Med. Genomics 2, 28 (2009).
9. Kim WS, Wong J, Weickert CS, Webster MJ, Bahn S, Garner B: Apolipoprotein-D expression is increased during development and maturation of the human prefrontal cortex. J. Neurochem. 109(4), 1053-1066 (2009).
10. Charnay Y, Imhof A, Vallet PG et al.: Clusterin expression during fetal and postnatal CNS development in mouse. Neuroscience 155(3), 714-724 (2008).
11. Li WH, Tanimura M, Luo CC, Datta S, Chan L: The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution. J. Lipid Res. 29(3), 245-271 (1988).
12. Hoofnagle AN, Heinecke JW: Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins. J. Lipid Res. 50(10), 1967-1975 (2009).
13. Beffert U, Stolt PC, Herz J: Functions of lipoprotein receptors in neurons. J. Lipid Res. 45(3), 403-409 (2004).
14. Qiu S, Korwek KM, Weeber EJ: A fresh look at an ancient receptor family: emerging roles for low density lipoprotein receptors in synaptic plasticity and memory formation. Neurobiol. Learn Mem. 85(1), 16-29 (2006).
15. Li Y, Cam J, Bu G: Low-density lipoprotein receptor family: endocytosis and signal transduction. Mol. Neurobiol. 23(1), 53-67 (2001).
16. Dietschy JM, Turley SD: Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45(8), 1375-1397 (2004).
17. Snipes GJ, Suter U: Cholesterol and myelin. Subcell. Biochem. 28, 173-204 (1997).
18. Bjorkhem I, Meaney S: Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24(5), 806-815 (2004).
19. Linton MF, Gish R, Hubl ST et al.: Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 88(1), 270-281 (1991).
20. Chobanian AV, Hollander W: Body cholesterol metabolism in man. I. The equilibration of serum and tissue cholesterol. J. Clin. Invest. 41, 1732-1737 (1962).
21. Meaney S, Hassan M, Sakinis A et al.: Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study. J. Lipid Res. 42(1), 70-78 (2001).
22. Plotz EJ, Kabara JJ, Davis ME, LeRoy GV, Gould RG: Studies on the synthesis of cholesterol in the brain of the human fetus. Am. J. Obstet. Gynecol. 101(4), 534-538 (1968).
23. Andersson M, Elmberger PG, Edlund C, Kristensson K, Dallner G: Rates of cholesterol, ubiquinone, dolichol and dolichyl-P biosynthesis in rat brain slices. FEBS Lett. 269(1), 15-18 (1990).
24. Bjorkhem I, Diczfalusy U, Lutjohann D: Removal of cholesterol from extrahepatic sources by oxidative mechanisms. Curr. Opin. Lipidol. 10(2), 161-165 (1999).
25. Roheim PS, Carey M, Forte T, Vega GL: Apolipoproteins in human cerebrospinal fluid. Proc. Natl Acad. Sci. USA 76(9), 4646-4649 (1979).
26. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH: Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem. 262(29), 14352-14360 (1987).
27. Borghini I, Barja F, Pometta D, James RW: Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim. Biophys. Acta 1255(2), 192-200 (1995).
28. Koch S, Donarski N, Goetze K et al.: Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res. 42(7), 1143-1151 (2001).
29. Suzuki T, Tozuka M, Kazuyoshi Y et al.: Predominant apolipoprotein J exists as lipid-poor mixtures in cerebrospinal fluid. Ann. Clin. Lab. Sci. 32(4), 369-376 (2002).
30. DeMattos RB, Brendza RP, Heuser JE et al.: Purification and characterization of astrocyte-secreted apolipoprotein E, J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem. Int. 39(5-6), 415-425 (2001).
31. LaDu M-J, Yu C, Youmans KL: Proposed mechanism for lipoprotein remodeling in the brain. Biochim. Biophys. Acta 1801(8), 819-823 (2010).
32. Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240(4852), 622-630 (1988).
33. Bao F, Arai H, Matsushita S, Higuchi S, Sasaki H: Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain. Neuroreport 7(11), 1733-1739 (1996).
34. Diedrich JF, Minnigan H, Carp RI et al.: Neuropathological changes in scrapie, Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J. Virol. 65(9), 4759-4768 (1991).
35. Han SH, Hulette C, Saunders AM et al.: Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Exp. Neurol. 128(1), 13-26 (1994).
36. Ignatius MJ, Gebicke-Harter PJ, Skene JH et al.: Expression of apolipoprotein E during nerve degeneration and regeneration. Proc. Natl Acad. Sci. USA 83(4), 1125-1129 (1986).
37. Metzger RE, LaDu MJ, Pan JB, Getz GS, Frail DE, Falduto MT: Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: implications for Alzheimer's disease. J Neuropathol. Exp. Neurol. 55(3), 372-380 (1996).
38. Nakai M, Kawamata T, Taniguchi T, Maeda K, Tanaka C: Expression of apolipoprotein E mRNA in rat microglia. Neurosci. Lett. 211(1), 41-44 (1996).
39. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE: Differential effects of apolipoproteins E3, E4 on neuronal growth in vitro. Science 264(5160), 850-852 (1994).
40. Poirier J, Hess M, May PC, Finch CE: Astrocytic apolipoprotein E mRNA, GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res. Mol. Brain Res. 11(2), 97-106 (1991).
41. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y: Profile and regulation of apolipoprotein E (APOE) expression in the CNS in mice with targeting of green fluorescent protein gene to the APOE locus. J. Neurosci. 26(19), 4985-4994 (2006).
42. Chang DJ, Paik YK, Leren TP, Walker DW, Howlett GJ, Taylor JM: Characterization of a human apolipoprotein E gene enhancer element and its associated protein factors. J. Biol. Chem. 265(16), 9496-9504 (1990).
43. Adroer R, Lopez-Acedo C, Oliva R: Conserved elements in the 5′ regulatory region of the amyloid precursor protein gene in primates. Neurosci. Lett. 226(3), 203-206 (1997).
44. Laffitte BA, Repa JJ, Joseph SB et al.: LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl Acad. Sci. USA 98(2), 507-512 (2001).
45. Salero E, Gimenez C, Zafra F: Identification of a non-canonical E-box motif as a regulatory element in the proximal promoter region of the apolipoprotein E gene. Biochem. J. 370(Pt 3), 979-986 (2003).
46. Lahiri DK: Apolipoprotein E as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene. J. Mol. Neurosci. 23(3), 225-233 (2004).
47. Du Y, Chen X, Wei X et al.: NF-kB mediates amyloid b peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells. Brain Res. Mol. Brain Res. 136(1-2), 177-188 (2005).
48. Naukkarinen J, Gentile M, Soro-Paavonen A et al.: USF1 and dyslipidemias: converging evidence for a functional intronic variant. Hum. Mol. Genet. 14(17), 2595-2605 (2005).
49. Ramos MC, Matias S, Artiga MJ et al.: Neuronal specific regulatory elements in apolipoprotein E gene proximal promoter. Neuroreport 16(9), 1027-1030 (2005).
50. Wahrle SE, Jiang H, Parsadanian M et al.: ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted ApoE. J. Biol. Chem. 279(39), 40987-40993 (2004).
51. Karten B, Campenot RB, Vance DE, Vance JE: Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia. J. Biol. Chem. 281(7), 4049-4057 (2006).
52. Kim WS, Rahmanto AS, Kamili A et al.: Role of ABCG1, ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-b peptide generation. J. Biol. Chem. 282(5), 2851-2861 (2007).
53. Hirsch-Reinshagen V, Wellington CL: Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, Alzheimer's disease. Curr. Opin. Lipidol. 18(3), 325-332 (2007).
54. Jansen PJ, Lutjohann D, Thelen KM et al.: Absence of ApoE upregulates murine brain ApoD, ABCA1 levels, but does not affect brain sterol levels, while human ApoE3 and human ApoE4 upregulate brain cholesterol precursor levels. J. Alzheimers Dis. 18(2), 319-329 (2009).
55. Terrisse L, Seguin D, Bertrand P, Poirier J, Milne R, Rassart E: Modulation of apolipoprotein D and apolipoprotein E expression in rat hippocampus after entorhinal cortex lesion. Brain Res. Mol. Brain Res. 70(1), 26-35 (1999).
56. Elshourbagy NA, Liao WS, Mahley RW, Taylor JM: Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc. Natl Acad. Sci. USA 82(1), 203-207 (1985).
57. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW: Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 917(1), 148-161 (1987).
58. Fagan AM, Holtzman DM, Munson G et al.: Unique lipoproteins secreted by primary astrocytes from wild type, apoE -/-, and human apoE transgenic mice. J. Biol. Chem. 274(42), 30001-30007 (1999).
59. Tarr PT, Edwards PA: ABCG1, ABCG4 are coexpressed in neurons and astrocytes of the CNS and regulate cholesterol homeostasis through SREBP-2. J. Lipid Res. 49(1), 169-182 (2008).
60. Burgess BL, Parkinson PF, Racke MM et al.: ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. J. Lipid Res. 49(6), 1254-1267 (2008).
61. Wang N, Yvan-Charvet L, Lutjohann D et al.: ATP-binding cassette transporters G1, G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain. FASEB J. 22(4), 1073-1082 (2008).
62. Rebeck GW, LaDu MJ, Estus S, Bu G, Weeber EJ: The generation and function of soluble apoE receptors in the CNS. Mol. Neurodegener. 1, 15 (2006).
63. Rall SC Jr, Weisgraber KH, Innerarity TL, Mahley RW: Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc. Natl Acad. Sci. USA 79(15), 4696-4700 (1982).
64. Corder EH, Saunders AM, Strittmatter WJ et al.: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261(5123), 921-923 (1993).
65. Strittmatter WJ, Saunders AM, Schmechel D et al.: Apolipoprotein E: high-avidity binding to b-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90(5), 1977-1981 (1993).
66. Harold D, Abraham R, Hollingworth P et al.: Genome-wide association study identifies variants at CLU, PICALM associated with Alzheimer's disease. Nat. Genet. 41(10), 1088-1093 (2009).
67. Lambert JC, Heath S, Even G et al.: Genome-wide association study identifies variants at CLU, CR1 associated with Alzheimer's disease. Nat. Genet. 41(10), 1094-1099 (2009).
68. Jordan BD: Genetic influences on outcome following traumatic brain injury. Neurochem. Res. 32(4-5), 905-915 (2007).
69. Jha A, Lammertse DP, Coll JR et al.: Apolipoprotein E e4 allele and outcomes of traumatic spinal cord injury. J. Spinal Cord Med. 31(2), 171-176 (2008).
70. Slooter AJ, Tang MX, van Duijn CM et al.: Apolipoprotein E e4 and the risk of dementia with stroke. A population-based investigation. JAMA 277(10), 818-821 (1997).
71. Huang X, Chen PC, Poole C: APOE-e2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 62(12), 2198-2202 (2004).
72. Beyreuther K, Masters CL: Amyloid precursor protein (APP) and b A4 amyloid in the etiology of Alzheimer's disease: precursor-product relationships in the derangement of neuronal function. Brain Pathol. 1(4), 241-251 (1991).
73. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K: Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541(1), 163-166 (1991).
74. Wisniewski T, Frangione B: Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135(2), 235-238 (1992).
75. Strittmatter WJ, Weisgraber KH, Huang DY et al.: Binding of human apolipoprotein E to synthetic amyloid b peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl Acad. Sci. USA 90(17), 8098-8102 (1993).
76. Jiang Q, Lee CY, Mandrekar S et al.: ApoE promotes the proteolytic degradation of Ab. Neuron 58(5), 681-693 (2008).
77. Gylys KH, Fein JA, Tan AM, Cole GM: Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-b protein into synaptic terminals. J. Neurochem. 84(6), 1442-1451 (2003).
78. Rebeck GW, Reiter JS, Strickland DK, Hyman BT: Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11(4), 575-580 (1993).
79. Urmoneit B, Prikulis I, Wihl G et al.: Cerebrovascular smooth muscle cells internalize Alzheimer amyloid b protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab. Invest. 77(2), 157-166 (1997).
80. Beffert U, Aumont N, Dea D, Lussier Cacan S, Davignon J, Poirier J: Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Brain Res. Mol. Brain Res. 68(1-2), 181-185 (1999).
81. Cole GM, Ard MD: Influence of lipoproteins on microglial degradation of Alzheimer's amyloid b-protein. Microsc. Res. Tech. 50(4), 316-324 (2000).
82. Yang DS, Small DH, Seydel U et al.: Apolipoprotein E promotes the binding and uptake of b-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience 90(4), 1217-1226 (1999).
83. Koistinaho M, Lin S, Wu X et al.: Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-b peptides. Nat. Med. 10(7), 719-726 (2004).
84. Deane R, Sagare A, Hamm K et al.: apoE isoform-specific disruption of amyloid b peptide clearance from mouse brain. J. Clin. Invest. 118(12), 4002-4013 (2008).
85. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE: Isoform-specific binding of apolipoprotein E to b-amyloid. J. Biol. Chem. 269(38), 23403-23406 (1994).
86. Schmechel DE, Saunders AM, Strittmatter WJ et al.: Increased amyloid b-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl Acad. Sci. USA 90(20), 9649-9653 (1993).
87. Nicoll JA, Roberts GW, Graham DI: Apolipoprotein E e 4 allele is associated with deposition of amyloid b-protein following head injury. Nat. Med. 1(2), 135-137 (1995).
88. Bales KR, Verina T, Cummins DJ et al.: Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 96(26), 15233-15238 (1999).
89. Holtzman DM, Bales KR, Wu S et al.: Expression of human apolipoprotein E reduces amyloid-b deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103(6), R1-R21 (1999).
90. Holtzman DM, Bales KR, Tenkova T et al.: Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 97(6), 2892-2897 (2000).
91. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM: Human and murine ApoE markedly alters A b metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9(3), 305-318 (2002).
92. Snipes GJ, McGuire CB, Norden JJ, Freeman JA: Nerve injury stimulates the secretion of apolipoprotein E by nonneuronal cells. Proc. Natl Acad. Sci. USA 83(4), 1130-1134 (1986).
93. Horsburgh K, Fitzpatrick M, Nilsen M, Nicoll JA: Marked alterations in the cellular localisation and levels of apolipoprotein E following acute subdural haematoma in rat. Brain Res. 763(1), 103-110 (1997).
94. Iwata A, Browne KD, Chen XH, Yuguchi T, Smith DH: Traumatic brain injury induces biphasic upregulation of ApoE, ApoJ protein in rats. J. Neurosci. Res 82(1), 103-114 (2005).
95. White F, Nicoll JA, Horsburgh K: Alterations in ApoE, ApoJ in relation to degeneration and regeneration in a mouse model of entorhinal cortex lesion. Exp. Neurol. 169(2), 307-318 (2001).
96. Aoki K, Uchihara T, Sanjo N et al.: Increased expression of neuronal apolipoprotein E in human brain with cerebral infarction. Stroke 34(4), 875-880 (2003).
97. Boschert U, Merlo-Pich E, Higgins G, Roses AD, Catsicas S: Apolipoprotein E expression by neurons surviving excitotoxic stress. Neurobiol. Dis. 6(6), 508-514 (1999).
98. Fagan AM, Murphy BA, Patel SN et al.: Evidence for normal aging of the septo-hippocampal cholinergic system in apoE-/-mice but impaired clearance of axonal degeneration products following injury. Exp. Neurol. 151(2), 314-325 (1998).
99. Chen Y, Lomnitski L, Michaelson DM, Shohami E: Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience 80(4), 1255-1262 (1997). (Pubitemid 27359807)
100. Pereira SG, Oakley F: Nuclear factor-kB1: regulation and function. Int. J. Biochem. Cell Biol. 40(8), 1425-1430 (2008).
101. Yamada T, Kondo A, Takamatsu J, Tateishi J, Goto I: Apolipoprotein E mRNA in the brains of patients with Alzheimer's disease. J. Neurol. Sci. 129(1), 56-61 (1995).
102. Yamagata K, Urakami K, Ikeda K et al.: High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 12(2), 57-62 (2001).
103. Thomas EA, Laws SM, Sutcliffe JG et al.: Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: no relation to apolipoprotein E expression or genotype. Biol. Psychiatry 54(2), 136-141 (2003).
104. Laws SM, Hone E, Taddei K et al.: Variation at the APOE-491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol. Psychiatry 7(8), 886-890 (2002).
105. Fukumoto H, Ingelsson M, Garevik N et al.: APOE e3/e4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp. Neurol. 183(1), 249-253 (2003).
106. Bertrand P, Poirier J, Oda T, Finch CE, Pasinetti GM: Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res. Mol. Brain Res. 33(1), 174-178 (1995).
107. Beffert U, Cohn JS, Petit-Turcotte C et al.: Apolipoprotein E and b-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 843(1-2), 87-94 (1999).
108. Glockner F, Meske V, Ohm TG: Genotype-related differences of hippocampal apolipoprotein E levels only in early stages of neuropathological changes in Alzheimer's disease. Neuroscience 114(4), 1103-1114 (2002).
109. Ramaswamy G, Xu Q, Huang Y, Weisgraber KH: Effect of domain interaction on apolipoprotein E levels in mouse brain. J. Neurosci. 25(46), 10658-10663 (2005).
110. Riddell DR, Zhou H, Atchison K et al.: Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J. Neurosci. 28(45), 11445-11453 (2008).
111. Sullivan PM, Mace BE, Maeda N, Schmechel DE: Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience 124(4), 725-733 (2004).
112. Fryer JD, Simmons K, Parsadanian M et al.: Human apolipoprotein E4 alters the amyloid-b 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25(11), 2803-2810 (2005).
113. Elliott DA, Tsoi K, Holinkova S et al.: Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiol. Aging DOI: 10.1016/j. neurobiolaging.2009.02.006 (2009) (Epub ahead of print).
114. Arai H, Kashiwagi S, Nagasaka Y, Uchida K, Hoshii Y, Nakamura K: Oxidative modification of apolipoprotein E in human very-low-density lipoprotein and its inhibition by glycosaminoglycans. Arch. Biochem. Biophys. 367(1), 1-8 (1999). (Pubitemid 29394186)
115. Elliott DA, Kim WS, Jans DA, Garner B: Apoptosis induces neuronal apolipoprotein-E synthesis and localization in apoptotic bodies. Neurosci. Lett. 416(2), 206-210 (2007).
116. Mahley RW, Nathan BP, Pitas RE: Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease. Ann NY Acad. Sci. 777, 139-145 (1996).
117. Mahley RW, Rall SC Jr: Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics. Hum. Genet. 1, 507-537 (2000).
118. Miyata M, Smith JD: Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and b-amyloid peptides. Nat. Genet. 14(1), 55-61 (1996).
119. Strittmatter WJ, Saunders AM, Goedert M et al.: Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc. Natl Acad. Sci. USA 91(23), 11183-11186 (1994).
120. Gelissen IC, Hochgrebe T, Wilson MR et al.: Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function? Biochem. J. 331(Pt 1), 231-237 (1998).
121. Jones SE, Jomary C: Clusterin. Int. J. Biochem. Cell Biol. 34(5), 427-431 (2002).
122. Wyatt AR, Yerbury JJ, Wilson MR: Structural characterization of clusterin-chaperone client protein complexes. J. Biol. Chem. 284(33), 21920-21927 (2009).
123. Rizzi F, Bettuzzi S: The clusterin paradigm in prostate and breast carcinogenesis. Endocr. Relat. Cancer 17(1), R1-17 (2010).
124. Wong P, Pineault J, Lakins J et al.: Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. J. Biol. Chem. 268(7), 5021-5031 (1993).
125. Rosemblit N, Chen CL: Regulators for the rat clusterin gene: DNA methylation and cis-acting regulatory elements. J. Mol. Endocrinol. 13(1), 69-76 (1994).
126. Michel D, Chatelain G, North S, Brun G: Stress-induced transcription of the clusterin/ apoJ gene. Biochem. J. 328(Pt 1), 45-50 (1997).
127. Loison F, Debure L, Nizard P, le Goff P, Michel D, le Drean Y: Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes. Biochem. J. 395(1), 223-231 (2006).
128. Ghiso J, Matsubara E, Koudinov A et al.: The cerebrospinal-fluid soluble form of Alzheimer's amyloid b is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. 293(Pt 1), 27-30 (1993).
129. Sasaki K, Doh-ura K, Ironside JW, Iwaki T: Increased clusterin (apolipoprotein J) expression in human and mouse brains infected with transmissible spongiform encephalopathies. Acta Neuropathol. 103(3), 199-208 (2002).
130. Freixes M, Puig B, Rodriguez A, Torrejon Escribano B, Blanco R, Ferrer I: Clusterin solubility and aggregation in Creutzfeldt-Jakob disease. Acta Neuropathol. 108(4), 295-301 (2004).
131. Kounnas MZ, Loukinova EB, Stefansson S et al.: Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. J. Biol. Chem. 270(22), 13070-13075 (1995).
132. Zlokovic BV, Martel CL, Matsubara E et al.: Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid b at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl Acad. Sci. USA 93(9), 4229-4234 (1996).
133. Bartl MM, Luckenbach T, Bergner O, Ullrich O, Koch-Brandt C: Multiple receptors mediate apoJ-dependent clearance of cellular debris into nonprofessional phagocytes. Exp. Cell Res. 271(1), 130-141 (2001).
134. Gardai SJ, McPhillips KA, Frasch SC et al.: Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123(2), 321-334 (2005).
135. Pasinetti GM, Johnson SA, Oda T, Rozovsky I, Finch CE: Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J. Comp. Neurol. 339(3), 387-400 (1994).
136. Garden GA, Bothwell M, Rubel EW: Lack of correspondence between mRNA expression for a putative cell death molecule (SGP-2) and neuronal cell death in the central nervous system. J. Neurobiol. 22(6), 590-604 (1991).
137. Dragunow M, Preston K, Dodd J, Young D, Lawlor P, Christie D: Clusterin accumulates in dying neurons following status epilepticus. Brain Res. Mol. Brain Res. 32(2), 279-290 (1995).
138. Yasuhara O, Aimi Y, Yamada T, Matsuo A, McGeer EG, McGeer PL: Clusterin as a marker for ischaemic Purkinje cells in human brain. Neurodegeneration 3(4), 325-329 (1994).
139. May PC, Lampert-Etchells M, Johnson SA, Poirier J, Masters JN, Finch CE: Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 5(6), 831-839 (1990).
140. Danik M, Chabot JG, Mercier C et al.: Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc. Natl Acad. Sci. USA 88(19), 8577-8581 (1991).
141. Wu E, Brosnan CF, Raine CS: SP-40,40 immunoreactivity in inflammatory CNS lesions displaying astrocyte/oligodendrocyte interactions. J. Neuropathol. Exp. Neurol. 52(2), 129-134 (1993).
142. Klimaschewski L, Obermuller N, Witzgall R: Regulation of clusterin expression following spinal cord injury. Cell Tissue Res. 306(2), 209-216 (2001).
143. Imhof A, Charnay Y, Vallet PG et al.: Sustained astrocytic clusterin expression improves remodeling after brain ischemia. Neurobiol. Dis. 22(2), 274-283 (2006).
144. Giannakopoulos P, Kovari E, French LE, Viard I, Hof PR, Bouras C: Possible neuroprotective role of clusterin in Alzheimer's disease: a quantitative immunocytochemical study. Acta Neuropathol. 95(4), 387-394 (1998).
145. Lidstrom AM, Bogdanovic N, Hesse C, Volkman I, Davidsson P, Blennow K: Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp. Neurol. 154(2), 511-521 (1998).
146. Kida E, Choi-Miura NH, Wisniewski KE: Deposition of apolipoproteins E, J in senile plaques is topographically determined in both Alzheimer's disease, Down's syndrome brain. Brain Res. 685(1-2), 211-216 (1995).
147. Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J: Apolipoprotein J (clusterin), Alzheimer's disease. Microsc. Res. Tech. 50(4), 305-315 (2000).
148. Wilson MR, Yerbury JJ, Poon S: Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol. Biosyst. 4(1), 42-52 (2008).
149. Bell RD, Sagare AP, Friedman AE et al.: Transport pathways for clearance of human Alzheimer's amyloid b-peptide and apolipoproteins E, J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 27(5), 909-918 (2007).
150. DeMattos RB, Cirrito JR, Parsadanian M et al.: ApoE and clusterin cooperatively suppress Ab levels and deposition: evidence that ApoE regulates extracellular Ab metabolism in vivo. Neuron 41(2), 193-202 (2004).
151. Nizard P, Tetley S, le Drean Y et al.: Stress-induced retrotranslocation of clusterin/ ApoJ into the cytosol. Traffic 8(5), 554-565 (2007).
152. Quinn CM, Kagedal K, Terman A et al.: Induction of fibroblast apolipoprotein E expression during apoptosis, starvation-induced growth arrest and mitosis. Biochem. J. 378(Pt 3), 753-761 (2004).
153. Kim WS, Elliott DA, Kockx M et al.: Analysis of apolipoprotein E nuclear localization using green fluorescent protein and biotinylation approaches. Biochem. J. 409(3), 701-709 (2008).
154. Do Carmo S, Levros LC, Jr, Rassart E: Modulation of apolipoprotein D expression and translocation under specific stress conditions. Biochim. Biophys. Acta 1773(6), 954-969 (2007).
155. Kang SW, Shin YJ, Shim YJ, Jeong SY, Park IS, Min BH: Clusterin interacts with SCLIP (SCG10-like protein) and promotes neurite outgrowth of PC12 cells. Exp. Cell Res. 309(2), 305-315 (2005).
156. Hashimoto M, Masliah E: Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with Lewy bodies. Neurochem. Res. 28(11), 1743-1756 (2003).
157. Klucken J, McLean PJ, Gomez-Tortosa E, Ingelsson M, Hyman BT: Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies. Neurochem. Res. 28(11), 1683-1691 (2003).
158. Rassart E, Bedirian A, Do Carmo S et al.: Apolipoprotein D. Biochim. Biophys. Acta 1482(1-2), 185-198 (2000).
159. Flower DR, North AC, Sansom CE: The lipocalin protein family: structural and sequence overview. Biochim. Biophys. Acta 1482(1-2), 9-24 (2000).
160. Pearlman WH, Gueriguian JL, Sawyer ME: A specific progesterone-binding component of human breast cyst fluid. J. Biol. Chem. 248(16), 5736-5741 (1973).
161. Lea OA: Binding properties of progesterone-binding Cyst protein, PBCP. Steroids 52(4), 337-338 (1988).
162. Dilley WG, Haagensen DE, Cox CE, Wells SA Jr: Immunologic and steroid binding properties of the GCDFP-24 protein isolated from human breast gross cystic disease fluid. Breast Cancer Res. Treat. 16(3), 253-260 (1990).
163. Morais Cabral JH, Atkins GL, Sanchez LM, Lopez-Boado YS, Lopez-Otin C, Sawyer L: Arachidonic acid binds to apolipoprotein D: implications for the protein's function. FEBS Lett. 366(1), 53-56 (1995).
164. Vogt M, Skerra A: Bacterially produced apolipoprotein D binds progesterone and arachidonic acid, but not bilirubin or E-3M2H. J. Mol. Recognit. 14(1), 79-86 (2001).
165. Provost PR, Villeneuve L, Weech PK, Milne RW, Marcel YL, Rassart E: Localization of the major sites of rabbit apolipoprotein D gene transcription by in situ hybridization. J. Lipid Res. 32(12), 1959-1970 (1991).
166. Smith KM, Lawn RM, Wilcox JN: Cellular localization of apolipoprotein D and lecithin:cholesterol acyltransferase mRNA in rhesus monkey tissues by in situ hybridization. J. Lipid Res. 31(6), 995-1004 (1990).
167. Thomas EA, Dean B, Pavey G, Sutcliffe JG: Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders. Proc. Natl Acad. Sci USA 98(7), 4066-4071 (2001).
168. Belloir B, Kovari E, Surini-Demiri M, Savioz A: Altered apolipoprotein D expression in the brain of patients with Alzheimer disease. J. Neurosci. Res 64(1), 61-69 (2001).
169. Lewis DA, Gonzalez-Burgos G: Pathophysiologically based treatment interventions in schizophrenia. Nat. Med. 12(9), 1016-1022 (2006).
170. Koenigs M, Grafman J: The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav. Brain Res. 201(2), 239-243 (2009).
171. Terrisse L, Poirier J, Bertrand P et al.: Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients. J. Neurochem. 71(4), 1643-1650 (1998).
172. Kalman J, McConathy W, Araoz C, Kasa P, Lacko AG: Apolipoprotein D in the aging brain and in Alzheimer's dementia. Neurol. Res. 22(4), 330-336 (2000).
173. Glockner F, Ohm TG: Hippocampal apolipoprotein D level depends on Braak stage, APOE genotype. Neuroscience 122(1), 103-110 (2003).
174. Ordonez C, Navarro A, Perez C, Astudillo A, Martinez E, Tolivia J: Apolipoprotein D expression in substantia nigra of Parkinson disease. Histol. Histopathol. 21(4), 361-366 (2006).
175. Franz G, Reindl M, Patel SC et al.: Increased expression of apolipoprotein D following experimental traumatic brain injury. J. Neurochem. 73(4), 1615-1625 (1999).
176. Rickhag M, Deierborg T, Patel S, Ruscher K, Wieloch T: Apolipoprotein D is elevated in oligodendrocytes in the peri-infarct region after experimental stroke: influence of enriched environment. J. Cereb. Blood Flow Metab. 28(3), 551-562 (2008).
177. Ong WY, He Y, Suresh S, Patel SC: Differential expression of apolipoprotein D and apolipoprotein E in the kainic acid-lesioned rat hippocampus. Neuroscience 79(2), 359-367 (1997).
178. Ong WY, Hu CY, Patel SC: Apolipoprotein D in the Niemann-Pick type C disease mouse brain: an ultrastructural immunocytochemical analysis. J. Neurocytol. 31(2), 121-129 (2002).
179. Suresh S, Yan Z, Patel RC, Patel YC, Patel SC: Cellular cholesterol storage in the Niemann-Pick disease type C mouse is associated with increased expression and defective processing of apolipoprotein D. J. Neurochem. 70(1), 242-251 (1998).
180. Do Carmo S, Seguin D, Milne R, Rassart E: Modulation of apolipoprotein D and apolipoprotein E mRNA expression by growth arrest and identification of key elements in the promoter. J. Biol. Chem. 277(7), 5514-5523 (2002).
181. Markesbery WR: Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23(1), 134-147 (1997).
182. Prabakaran S, Swatton JE, Ryan MM et al.: Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 9(7), 684-697, 643 (2004). (Pubitemid 38932173)
183. Onyango IG, Khan SM: Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. Curr. Alzheimer Res. 3(4), 339-349 (2006).
184. Ganfornina MD, Do Carmo S, Lora JM et al.: Apolipoprotein D is involved in the mechanisms regulating protection from oxidative stress. Aging Cell 7(4), 506-515 (2008).
185. Sanchez D, Lopez-Arias B, Torroja L et al.: Loss of glial lazarillo, a homolog of apolipoprotein D, reduces lifespan and stress resistance in Drosophila. Curr. Biol. 16(7), 680-686 (2006).
186. Walker DW, Muffat J, Rundel C, Benzer S: Overexpression of a Drosophila homolog of apolipoprotein D leads to increased stress resistance and extended lifespan. Curr. Biol. 16(7), 674-679 (2006).
187. Do Carmo S, Jacomy H, Talbot PJ, Rassart E: Neuroprotective effect of apolipoprotein D against human coronavirus OC43-induced encephalitis in mice. J. Neurosci. 28(41), 10330-10338 (2008).
188. Muffat J, Walker DW, Benzer S: Human ApoD, an apolipoprotein up-regulated in neurodegenerative diseases, extends lifespan and increases stress resistance in Drosophila. Proc. Natl Acad. Sci. USA 105(19), 7088-7093 (2008).
189. Boyles JK, Notterpek LM, Anderson LJ: Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. Identification of apolipoprotein D, apolipoprotein A-IV, apolipoprotein E, and apolipoprotein A-I. J. Biol. Chem. 265(29), 17805-17815 (1990).
190. Seguin D, Desforges M, Rassart E: Molecular characterization and differential mRNA tissue distribution of mouse apolipoprotein D. Brain Res. Mol. Brain Res. 30(2), 242-250 (1995).
191. Desai PP, Ikonomovic MD, Abrahamson EE et al.: Apolipoprotein D is a component of compact but not diffuse amyloid-b plaques in Alzheimer's disease temporal cortex. Neurobiol. Dis. 20(2), 574-582 (2005).
192. Price DL, Tanzi RE, Borchelt DR, Sisodia SS: Alzheimer's disease: genetic studies and transgenic models. Annu. Rev. Genet. 32, 461-493 (1998).
193. Hiltunen M, Mannermaa A, Thompson D et al.: Genome-wide linkage disequilibrium mapping of late-onset Alzheimer's disease in Finland. Neurology 57(9), 1663-1668 (2001).
194. Desai PP, Hendrie HC, Evans RM, Murrell JR, DeKosky ST, Kamboh MI: Genetic variation in apolipoprotein D affects the risk of Alzheimer disease in African-Americans. Am. J. Med. Genet. B Neuropsychiatr. Genet. 116B(1), 98-101 (2003).
195. Lewis CM, Levinson DF, Wise LH et al.: Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am. J. Hum. Genet. 73(1), 34-48 (2003).
196. Hansen T, Hemmingsen RP, Wang AG et al.: Apolipoprotein D is associated with long-term outcome in patients with schizophrenia. Pharmacogenomics J. 6(2), 120-125 (2006).
197. Thomas EA, Danielson PE, Nelson PA et al.: Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy. J. Neurochem. 76(3), 789-796 (2001).
198. Thomas EA, George RC, Danielson PE et al.: Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol. Psychiatry 8(12), 983-993, 950 (2003).
199. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH: Plasma lipoproteins: apolipoprotein structure and function. J. Lipid Res. 25(12), 1277-1294 (1984).
200. Harr SD, Uint L, Hollister R, Hyman BT, Mendez AJ: Brain expression of apolipoproteins E, J, A-I in Alzheimer's disease. J. Neurochem. 66(6), 2429-2435 (1996).
201. Huang JT, Wang L, Prabakaran S et al.: Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol. Psychiatry 13(12), 1118-1128 (2008).
202. Weiler-Guttler H, Sommerfeldt M, Papandrikopoulou A et al.: Synthesis of apolipoprotein A-1 in pig brain microvascular endothelial cells. J. Neurochem. 54(2), 444-450 (1990).
203. Mockel B, Zinke H, Flach R, Weiss B, Weiler-Guttler H, Gassen HG: Expression of apolipoprotein A-I in porcine brain endothelium in vitro. J. Neurochem. 62(2), 788-798 (1994).
204. Vollbach H, Heun R, Morris CM et al.: APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann. Neurol. 58(3), 436-441 (2005).
205. Tuteja R, Tuteja N, Melo C, Casari G, Baralle FE: Transcription efficiency of human apolipoprotein A-I promoter varies with naturally occurring A to G transition. FEBS Lett. 304(1), 98-101 (1992).
206. Angotti E, Mele E, Costanzo F, Avvedimento EV: A polymorphism (G->A transition) in the -78 position of the apolipoprotein A-I promoter increases transcription efficiency. J. Biol. Chem. 269(26), 17371-17374 (1994).
207. Jeenah M, Kessling A, Miller N, Humphries S: G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol. Biol. Med. 7(3), 233-241 (1990).
208. Juo SH, Wyszynski DF, Beaty TH, Huang HY, Bailey-Wilson JE: Mild association between the A/G polymorphism in the promoter of the apolipoprotein A-I gene and apolipoprotein A-I levels: a meta analysis. Am. J. Med. Genet. 82(3), 235-241 (1999).
209. Demeester N, Castro G, Desrumaux C et al.: Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. J. Lipid Res. 41(6), 963-974 (2000).
210. Kang J, Lemaire HG, Unterbeck A et al.: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325(6106), 733-736 (1987).
211. Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS: Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A b aggregation and toxicity. Biochemistry 40(12), 3553-3560 (2001).
212. Petit-Turcotte C, Stohl SM, Beffert U et al.: Apolipoprotein C-I expression in the brain in Alzheimer's disease. Neurobiol. Dis. 8(6), 953-963 (2001).
213. Lauer SJ, Walker D, Elshourbagy NA, Reardon CA, Levy-Wilson B, Taylor JM: Two copies of the human apolipoprotein C-I gene are linked closely to the apolipoprotein E gene. J. Biol. Chem. 263(15), 7277-7286 (1988).
214. Shen P, Howlett GJ: Two coding regions closely linked to the rat apolipoprotein E gene: nucleotide sequences of rat apolipoprotein C-I, ECL cDNA. Arch. Biochem. Biophys. 297(2), 345-353 (1992).
215. Tysoe C, Galinsky D, Robinson D et al.: APO E, APO CI loci are associated with dementia in younger but not older late-onset cases. Dement. Geriatr. Cogn. Disord. 9(4), 191-198 (1998).
216. Poduslo SE, Neal M, Herring K, Shelly J: The apolipoprotein CI A allele as a risk factor for Alzheimer's disease. Neurochem. Res. 23(3), 361-367 (1998).
217. Drigalenko E, Poduslo S, Elston R: Interaction of the apolipoprotein E, CI loci in predisposing to late-onset Alzheimer's disease. Neurology 51(1), 131-135 (1998).
218. Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS: Apolipoprotein C-I modulates the interaction of apolipoprotein E with b-migrating very low density lipoproteins (b-VLDL) and inhibits binding of b-VLDL to low density lipoprotein receptor-related protein. J. Biol. Chem. 265(36), 22453-22459 (1990).
219. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL: Opposing effects of apolipoproteins E, C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem. 265(18), 10771-10779 (1990).
220. Sehayek E, Eisenberg S: Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J. Biol. Chem. 266(27), 18259-18267 (1991).
221. Liu M, Doi T, Shen L et al.: Intestinal satiety protein apolipoprotein AIV is synthesized and regulated in rat hypothalamus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280(5), R1382-R1387 (2001).
222. Shen L, Pearson KJ, Xiong Y et al.: Characterization of apolipoprotein A-IV in brain areas involved in energy homeostasis. Physiol. Behav. 95(1-2), 161-167 (2008).
223. Okumura T, Fukagawa K, Tso P, Taylor IL, Pappas TN: Intracisternal injection of apolipoprotein A-IV inhibits gastric secretion in pylorus-ligated conscious rats. Gastroenterology 107(6), 1861-1864 (1994).
224. Tso P, Chen Q, Fujimoto K, Fukagawa K, Sakata T: Apolipoprotein A-IV: a circulating satiety signal produced by the small intestine. Obes. Res. 3(Suppl. 5), 689S-695S (1995).
225. Tso P, Liu M, Kalogeris TJ: The role of apolipoprotein A-IV in food intake regulation. J. Nutr. 129(8), 1503-1506 (1999).
226. Csaszar A, Kalman J, Szalai C, Janka Z, Romics L: Association of the apolipoprotein A-IV codon 360 mutation in patients with Alzheimer's disease. Neurosci. Lett. 230(3), 151-154 (1997).
227. Mimmack ML, Ryan M, Baba H et al.: Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22. Proc. Natl Acad. Sci. USA 99(7), 4680-4685 (2002).
228. Takahashi S, Cui YH, Han YH et al.: Association of SNPs and haplotypes in APOL1, 2 and 4 with schizophrenia. Schizophr. Res. 104(1-3), 153-164 (2008).
229. Vanhollebeke B, Pays E: The function of apolipoproteins L. Cell Mol. Life Sci. 63(17), 1937-1944 (2006).
230. Rebeck GW, Alonzo NC, Berezovska O et al.: Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes. Exp. Neurol. 149(1), 175-182 (1998).
231. Montine KS, Bassett CN, Ou JJ, Markesbery WR, Swift LL, Montine TJ: Apolipoprotein E allelic influence on human cerebrospinal fluid apolipoproteins. J. Lipid Res. 39(12), 2443-2451 (1998).
232. Caronti B, Calderaro C, Alessandri C et al.: b2-glycoprotein I (b2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Clin. Exp. Immunol. 115(1), 214-219 (1999).
233. Fujimoto K, Fukagawa K, Sakata T, Tso P: Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats. J. Clin. Invest. 91(4), 1830-1833 (1993).
234. Eckert GP, Vardanian L, Rebeck GW, Burns MP: Regulation of central nervous system cholesterol homeostasis by the liver X receptor agonist TO-901317. Neurosci. Lett. 423(1), 47-52 (2007).
235. Koldamova RP, Lefterov IM, Staufenbiel M et al.: The liver X receptor ligand T0901317 decreases amyloid b production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem. 280(6), 4079-4088 (2005).
236. Sun Y, Yao J, Kim TW, Tall AR: Expression of liver X receptor target genes decreases cellular amyloid b peptide secretion. J. Biol. Chem. 278(30), 27688-27694 (2003).
237. Ruscher K, Erickson A, Kuric E, Inacio AR, Wieloch T: Effects of chronic clozapine administration on apolipoprotein D levels and on functional recovery following experimental stroke. Brain Res. 1321, 152-163 (2010).
238. Aono M, Bennett ER, Kim KS et al.: Protective effect of apolipoprotein E-mimetic peptides on N-methyl-d-aspartate excitotoxicity in primary rat neuronal-glial cell cultures. Neuroscience 116(2), 437-445 (2003).
239. Laskowitz DT, Fillit H, Yeung N, Toku K, Vitek MP: Apolipoprotein E-derived peptides reduce CNS inflammation: implications for therapy of neurological disease. Acta Neurol. Scand. Suppl. 185, 15-20 (2006).
240. Laskowitz DT, Thekdi AD, Thekdi SD et al.: Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp. Neurol. 167(1), 74-85 (2001).
241. Laskowitz DT, McKenna SE, Song P et al.: COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J. Neurotrauma 24(7), 1093-1107 (2007).
242. Wang H, Durham L, Dawson H et al.: An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction. Neuroscience 144(4), 1324-1333 (2007).
243. Li FQ, Sempowski GD, McKenna SE, Laskowitz DT, Colton CA, Vitek MP: Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. J. Pharmacol. Exp. Ther. 318(3), 956-965 (2006).
244. Gao J, Wang H, Sheng H et al.: A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. Neurocrit. Care 4(1), 25-31 (2006).
245. James ML, Sullivan PM, Lascola CD, Vitek MP, Laskowitz DT: Pharmacogenomic effects of apolipoprotein E on intracerebral hemorrhage. Stroke 40(2), 632-639 (2009).
246. Sarantseva S, Timoshenko S, Bolshakova O et al.: Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease. PLoS One 4(12), E8191 (2009).
247. Navab M, Ruchala P, Waring AJ et al.: A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all l-amino acids. J. Lipid Res. 50(8), 1538-1547 (2009).
248. Kratzer I, Wernig K, Panzenboeck U et al.: Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J. Control Release 117(3), 301-311 (2007).
249. Brasnjevic I, Steinbusch HW, Schmitz C, Martinez-Martinez P: Delivery of peptide and protein drugs over the blood-brain barrier. Prog. Neurobiol. 87(4), 212-251 (2009).
250. Sarantseva SV, Bol'shakova OI, Timoshenko SI, Kolobov AA, Vitek MP, Shvartsman AL: [Protein transduction domain peptide mediates delivery to the brain via the blood-brain barrier in Drosophila]. Biomed. Khim. 55(1), 41-49 (2009).
251. Medline Plus. Online dictionary www.nlm.nih.gov/medlineplus/ mplusdictionary.html
252. National Center for Biotechnology Information. Gene expression omnibus www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13564